Organigram: Aurora Cannabis Acquisition Valued At C$561 Million To Create Global Cannabis Platform
Organigram will acquire Aurora Cannabis for C$561M. Aurora shareholders can receive C$7.80 per share in cash, Organigram shares, or a mix. The deal aims to create a global cannabis platform with C$50M in expected synergies. British American Tobacco is supporting the acquisition. Completion is expected in January 2027, pending approvals.
How this was made
The 30-second read
Why it matters
The merger creates a vertically integrated player with both recreational and medical capabilities, potentially improving margins and market reach.
Market read
The deal reshapes the competitive landscape of the global cannabis market and offers immediate trading opportunities for both stocks.
What to watch
Regulatory approvals in Europe and Australia could delay closing and affect valuation.
Background
The cannabis industry has seen heightened consolidation as companies seek scale to meet global regulatory standards.
Ticker impact
Aurora Cannabis is being acquired by Organigram at C$7.80 per share, a 93% premium to its recent price.
likely downward pressure as shareholders trade the premium and the loss of a standalone stock.
The acquisition ends Aurora's independent trading; premium‑paid acquisitions often trigger a sell‑off of the target's shares.
Market effects
Consolidates the Canadian cannabis sector, potentially prompting further M&A activity.
Strengthens North American and European cannabis supply chains.
Creates one of the largest globally diversified cannabis companies, affecting investor sentiment toward the broader cannabis industry.
Counterpoint
The premium may be excessive; integration risks could erode expected synergies.
Key entities
- CompanyOrganigram Global
Canadian cannabis producer acquiring Aurora.
- CompanyAurora Cannabis
Canadian medical cannabis producer being acquired.
- InvestorBritish American Tobacco
Strategic investor supporting the deal via a private placement.
